GLMD - Galmed Pharmaceuticals Ltd.
| Previous Close | 5.99 |
| Open | 5.99 |
| Bid | 6.31 x 1300 |
| Ask | 6.36 x 900 |
| Day's Range | 5.90 - 6.37 |
| 52 Week Range | 3.42 - 9.74 |
| Volume | 71,088 |
| Avg. Volume | 109,160 |
| Market Cap | 134M |
| Beta (3Y Monthly) | 2.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.70 |
- Zacks
Top Ranked Momentum Stocks to Buy for December 4th
Top Ranked Momentum Stocks to Buy for December 4th
- Zacks
NASH Scorecard Year to Date: The Winners and the Losers
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
- Thomson Reuters StreetEvents
Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call
- PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- Simply Wall St.
Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60%
This week we saw the Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) share price climb by 22%. But that isn't much...
- PR Newswire
Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new data at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 8-12, 2019. This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models.
- PR Newswire
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- PR Newswire
Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled, global study will be conducted in approximately 185 sites in the U.S., Europe, Latin America and Asia. The ARMOR study will evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes. A total of 2000 subjects will be randomized 2:1 to receive Aramchol 300mg BID or matching placebo.
- Simply Wall St.
Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason?
Trailing twelve-month data shows us that Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) earnings loss has accumulated to...
- Thomson Reuters StreetEvents
Edited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMT
Q2 2019 Galmed Pharmaceuticals Ltd Earnings Call
- PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- PR Newswire
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
TEL AVIV, Israel , July 29, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Simply Wall St.
Could The Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ownership Structure Tell Us Something Useful?
Every investor in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) should be aware of the most powerful shareholder groups...
- Simply Wall St.
Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Being Overpaid?
In 2012 Allen Baharaff was appointed CEO of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD). This report will, first...
- Zacks
Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Galmed Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
- PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- PR Newswire
Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
TEL AVIV, Israel , April 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- PR Newswire
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
TEL AVIV, Israel, April 9, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, announced today that the company has completed its End-of-Phase 2 meeting with the Food and Drug Administration (FDA) and reached general agreement on key aspects of the Phase 3/4 development and registration plan for Aramchol and on the pivotal registration study ARMOR. ARMOR is a Phase 3/4 multinational, multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of Aramchol in subjects with NASH and fibrosis.
- Zacks
Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- Simply Wall St.
Update: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three Years
It hasn't been the best quarter for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shareholders, since the share price has fallen 17% in that time. But that doesn't change the fact that theRead More...
- PR Newswire
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
The aim of this Phase I, open-label, two-period, randomized, crossover PK study was to assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took part in two study periods.
- PR Newswire
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel , March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Zacks
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
